Changing the "channel": aminopyridines potentiate synaptic and neuromuscular transmission by targeting the voltage-activated calcium channel beta subunit.
D015761:4-Aminopyridine / Q000494:pharmacology*; D000818:Animals; D002118:Calcium / Q000378:metabolism; D002121:Calcium Channel Blockers / Q000494:pharmacology; D020864:Calcium Channels, N-Type / Q000235:genetics / Q000378:metabolism*; D020747:Calcium Channels, T-Type / Q000235:genetics / Q000378:metabolism*; D005727:Ganglia, Spinal / Q000378:metabolism; D006801:Humans; D008297:Male; D009103:Multiple Sclerosis / Q000235:genetics / Q000378:metabolism; D009157:Myasthenia Gravis / Q000235:genetics / Q000378:metabolism; D009469:Neuromuscular Junction / Q000378:metabolism*; D009474:Neurons / Q000378:metabolism; D026902:Potassium Channel Blockers / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013119:Spinal Cord Injuries / Q000235:genetics / Q000378:metabolism; D009435:Synaptic Transmission / Q000187:drug effects*
C500545:CACNA1B protein, human; C479952:CACNA1H protein, human; C503279:Cacna1b protein, rat; C509958:Cacna1h protein, rat; D002121:Calcium Channel Blockers; D020864:Calcium Channels, N-Type; D020747:Calcium Channels, T-Type; D026902:Potassium Channel Blockers; D015761:4-Aminopyridine; D002118:Calcium